Skip to content

Characterization of the Mechanisms of Resistance to Azacitidine

Characterization of the Mechanisms of Action of Resistance to Azacitidine in High-risk Myelodysplastic Syndromes and Acute Myeloid Leukemia With Multilineage Dysplasia

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01210274
Enrollment
250
Registered
2010-09-28
Start date
2010-09-30
Completion date
2025-09-30
Last updated
2025-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myelodysplastic Syndromes or Acute Myeloid Leukemia With Multilineage Dysplasia

Brief summary

Myelodysplastic syndromes (MDS) are frequent diseases in elderly patients (median age: 71 years). IPSS classification defines low risk (Low and Intermediate 1), and high risk (Intermediate 2 and High) MDS. High-risk MDS (MDS-HR) have a high risk of transformation into acute leukemia with multilineage dysplasia (AML-DML). The success of Azacitidine has been mainly achieved through a rigorous empirical and clinical research, but the molecular mechanisms by which this molecule exerts its effects remain poorly characterized. The primary mode of action of Azacytidine is through DNA demethylation, and integration in to mRNA that favor traduction inhibition. The impact of this molecule on various cell death programs involved in the elimination of leukemic cells : apoptosis and autophagy is currently poorly known. The research program and clinical studies we proposed focus on two major aspects: \- Main objective: Molecular mechanism of action and resistance to Azacitidine: Role of apoptosis versus autophagy. \- Secondary Objective: Reversion of Azacytidine resistance using different drugs targeting apoptosis and/or autophagy. Our laboratory has identified new molecules to selectively induce different types of cell death (apoptosis or autophagy).

Interventions

None listed

Sponsors

Centre Hospitalier Universitaire de Nice
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 years * High Risk or Intermediate 2 MDS (IPSS) * AML-MD (WHO classification) * Treatment with minimum three to six cycles of Azacitidine * Informed consent form signed

Exclusion criteria

* Treatment with others chemotherapies alone or in association

Design outcomes

Primary

MeasureTime frameDescription
hematological responseat 3 monthsHematological response evaluated by the International Working Group (IWG) response of Cheson

Secondary

MeasureTime frameDescription
Overall survivalDay 1 of treatmentOverall survival (OS) defined as the time from start of treatment

Countries

France, Monaco

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 10, 2026